ARVEEArvee Laboratories (India) Limited
Chemicals · Specialty Chemicals · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Arvee Laboratories (India) Ltd. manufactures and sells various specialized chemicals in India. The company offers polymer modifiers, including dimethyl 5-sodiosulfoisophthalate, 5-sulfoisophthalic acid mono sodium salt, 5-sulfoisophthalic acid mono lithium salt, and 5-sodiosulfo-bis-(ß-hydroxyethyl)-isophthalate; and contrast media intermediates, such as 5-nitroisophthalic acid, dimethyl 5-nitroisophthalate, monomethyl 5-nitroisophthalate, 5-hydroxyisophthalic acid, 5-aminoisophthalic acid, and dimethyl 5-aminoisophthalate, as well as 3,5-dinitrobenzoic acid and 3,5-diamino benzoic acid. It also provides drug intermediates comprising 2-acetyl thiophene, thiophene-2-carboxaldehyde, 4amino pyridine, and 2chloro5nitrobenzoic acid. In addition, the company exports its products. Arvee Laboratories (India) Ltd. was incorporated in 2012 and is based in Ahmedabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on ARVEE — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 39/100)
- • ROE: 7.5%
- • ROCE: 7.6%
- • RSI: 37
- • MACD: bearish
Bull case
- • Revenue growth: 130.3% YoY
- • Profit growth: 926.7% YoY
- • Debt/Equity: 0.03
- • Price vs SMA200: above
Bear case
- • ROE: 7.5%
- • ROCE: 7.6%
- • RSI: 37
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Momentum is fading versus the broader market
- • ROE: 7.5%
- • ROCE: 7.6%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹16.44). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.